Clinical trials: Metastatic Malignant Neoplasm in the Peritoneum
Gastric Cancer Peritoneal Metastases
Safety and Efficacy of Systemic Chemotherapy Plus PD-1 Inhibitor in Combination With Bevacizumab in Gastric Cancer With Peritoneal Metastasis
It is an open label, phase II study involved receiving albumin-bound paclitaxel plus S-1 combined with sintilimab and bevacizumab in patients with gastric cancer peritoneal metastasis.
- Trial name
- NCT06487715
- Testing
- albumin-bound paclitaxel (260 mg/m2, d1), S-1, sintilimab
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing.
- Conditions
- Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Malignant Solid Neoplasm
- Trial name
- NCT05564377
- Testing
- Alpelisib, Binimetinib, Biopsy Procedure
- Where
- 484 sites in United States, Puerto Rico
- Volunteers
- 2,900 people
- Sponsor
- National Cancer Institute (NCI)
Peritoneal Metastasis, Gastric Cancer
The Role of 18F-FDG&68Ga-FAPI PET/CT in the Assessment of Conversion Therapy Efficacy in Gastric Cancer with Peritoneal Metastasis.
This study aims to investigate the value of 18F-FDG\&68Ga-FAPI PET/CT in evaluating the outcome of conversion therapy and the prognosis of people with peritoneal metastases from gastric cancer.
- Trial name
- NCT06597526
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Ruijin Hospital